Document is current
Any future updates will be listed below
-
Authors
DiNardo, Courtney D. https://orcid.org/0000-0001-9003-0390
Verma, Divij https://orcid.org/0000-0002-2214-9450
Baran, Natalia https://orcid.org/0000-0003-0618-4798
Bhagat, Tushar D.
Skwarska, Anna
Lodi, Alessia
Saxena, Kapil
Cai, Tianyu https://orcid.org/0000-0002-5271-3235
Su, Xiaoping
Guerra, Veronica A. https://orcid.org/0000-0002-4219-7708
Poigaialwar, Gowri https://orcid.org/0000-0002-8882-7146
Kuruvilla, Vinitha M.
Konoplev, Sergej
Gordon-Mitchell, Shanisha
Pradhan, Kith
Aluri, Srinivas
Hackman, G. Lavender https://orcid.org/0000-0001-7439-5138
Chaudhry, Sovira
Collins, Meghan https://orcid.org/0000-0002-6201-9298
Sweeney, Shannon R.
Busquets, Jonathan
Rathore, Atul Singh
Deng, Qing
Green, Michael R. https://orcid.org/0000-0001-6309-9472
Grant, Steven
Demo, Susan
Choudhary, Gaurav S.
Sahu, Srabani
Agarwal, Beamon
Spodek, Mason
Thiruthuvanathan, Victor
Will, Britta
Steidl, Ulrich
Tippett, George D.
Burger, Jan
Borthakur, Gautam https://orcid.org/0000-0001-7679-6453
Jabbour, Elias https://orcid.org/0000-0003-4465-6119
Pemmaraju, Naveen
Kadia, Tapan https://orcid.org/0000-0002-9892-9832
Kornblau, Steven https://orcid.org/0000-0002-5990-9548
Daver, Naval G. https://orcid.org/0000-0001-7103-373X
Naqvi, Kiran
Short, Nicholas J.
Garcia-Manero, Guillermo https://orcid.org/0000-0002-3631-2482
Tiziani, Stefano https://orcid.org/0000-0002-7230-0307
Verma, Amit https://orcid.org/0000-0002-5408-1673
Konopleva, Marina https://orcid.org/0000-0002-9347-2212
- License Information
-
More Information
Article History
Received: 26 January 2023
Accepted: 24 July 2024
First Online: 19 September 2024
Competing interests
: A.V. has received research funding from Prelude, Ryvu, BMS, GSK, Incyte, Medpacto, Curis and Eli Lilly, is a scientific advisor for Stelexis, Aurigene, Acceleron and Celgene, receives honoraria from Stelexis, Aurigene and Janssen and holds equity in Stelexis and Clinstreet. K.S. is a current employee of Gilead Sciences, Inc. All work contributing to the paper was performed while at the University of Texas MD Anderson Cancer Center. N.J.S. has received consulting fees from Pfizer Inc., GSK, NKARTA, Autolus, Adaptive Biotechnologies and Sanofi and research funding from Takeda Oncology, Astellas Pharma Inc., Xencor, GSK, NextCure, Ascentage and Novartis. N.J.S. receives honoraria from Adaptive Biotechnologies, Amgen, Takeda, Pfizer Inc., Astellas Pharma Inc. and Sanofi. C.D.D. is a consultant and/or on the advisory board of Abbvie, AstraZeneca, Astellas, BMS, Genentech, GenMab, GSK, Notable Labs, Rigel, Ryvu, Schrodinger and Servier. S. Konoplev is consultant for Cairo Diagnostics Laboratory. G.S.C. has stock options in privately held company Curis. M.R.G. reports research funding from Sanofi, Kite/Gilead, Abbvie and Allogene; consulting for Abbvie and Allogene; advisory board for Bristol Myers Squibb, Arvinas and Johnson & Johnson; honoraria from BMS, Daiichi Sankyo and DAVA Oncology; and stock ownership of KDAc Therapeutics. S.D. is employed at Calithera. M.K. received research support from Calithera. U.S. has received research funding from GlaxoSmithKline, Bayer Healthcare, Aileron Therapeutics and Novartis; has received compensation for consultancy services and for serving on scientific advisory boards from GlaxoSmithKline, Bayer Healthcare, Celgene, Aileron Therapeutics, Stelexis Therapeutics and Pieris Pharmaceuticals; and has equity ownership in and has served on the board of directors of Stelexis Therapeutics. The other authors declare no competing interests.
